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ABSTRACT
Objective To assess the distribution of high-sensitivity
cardiac troponin T (hs-cTnT) concentrations in stable
chronic obstructive pulmonary disease (COPD), and
whether hs-cTnT is associated with pulmonary function.
Design Prospectively designed, cross-sectional study.
Setting Outpatient clinic of Norwegian teaching
hospital and community-based setting.
Participants Sample of 101 stable COPD patients
from the hospital’s outpatient clinic and 120 individuals
derived from a random general population sample.
Main outcomes Ratio of hs-cTnT in stable COPD
patients compared with references from the general
population. Change in ratio of hs-cTnT per unit increase
of relevant covariables.
Results The crude geometric means of circulating hs-
cTnT in the cases and the references were 7.75 and
3.01 ng/l, respectively (p <0.001); that is, a relative ratio
of 2.57 (95% CI 2.05 to 3.23). After adjustment for
relevant confounders, this ratio was moderately
attenuated to 1.65 (1.31–2.08). In the total study
cohort, as well as among stable COPD patients, we
found a signiﬁcant positive association between hs-cTnT
and interleukin-6 concentrations (p <0.001) and the
presence of pathologic Q waves (p=0.023). Among
stable COPD patients, one quartile increase in forced
expiratory volume 1 was associated with a 39%
decrease in hs-cTnT and patient category (Global
Initiative of Obstructive Lung Disease classiﬁcation
2011) was positively associated with hs-cTnT (p trend
<0.001) after multivariate adjustment.
Conclusions Stable COPD is independently associated
with higher hs-cTnT compared with randomly drawn
subjects from the general population. In patients with
stable COPD, higher hs-cTnT seems to be associated
with immune activation and the severity of the disease.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
major cause of chronic morbidity and mortality
throughout the world. The international organisa-
tion, Global Initiative of Obstructive Lung Disease
(GOLD), published their ﬁrst deﬁnition of COPD in
2001. This deﬁnition focused almost exclusively on
irreversible airﬂow limitation, airway inﬂammation
and emphysema, in addition to tobacco smoking
and environmental exposures. During the last few
years, the inﬂammatory components and extrapul-
monary comorbidities of COPD manifested as car-
diovascular disease, osteoporosis or skeletal muscle
wasting have attracted increasing attention.1 2 In
addition to the chronic progressive aspect of COPD,
many COPD patients have acute worsening of
their symptoms (ie, exacerbation), frequently
leading to hospitalisation and increased mortality.3
Retrospective, as well as prospective studies, have
indicated that even modest troponin elevations
among COPD patients hospitalised for exacerbation
are associated with increased mortality.4 5
Detection of cardiac troponin T (cTnT) or
cardiac troponin I (cTnI) above the 99th percentile
of a reference population is a prerequisite for the
diagnosis of acute myocardial infarction (MI).6 In
several chronic diseases, such as chronic renal
failure and heart failure, chronically elevated
cardiac troponin levels have been described in the
stable state of the disease.7 The new, highly sensi-
tive (hs) assay for cardiac troponin T measures con-
centrations that are ﬁvefold to tenfold lower than
conventional assays, and the great majority of
patients with stable coronary artery disease (CAD)
have detectable levels of cTnT.8 By contrast, with
the conventional assay for cTnT, <1% of subjects
in the general population have detectable levels.9
High-sensitivity cardiac troponin T (hs-cTnT)
levels above the detection limit are associated with
cardiac structure and impaired function, and pre-
dictive of heart failure, cardiovascular death and all-
cause mortality.10 11 Previous studies evaluating the
association between COPD and troponin T have
mainly focused on patients with COPD exacerba-
tions, or have used COPD as a covariate for
comorbidity. A recently published study showed that
acute exacerbation of COPD is associated with
higher hs-cTnT compared with stable COPD
patients recruited at a rehabilitation hospital, and
that hs-cTnT was associated with COPD severity.12
To the best of our knowledge, there are, at present,
no further studies evaluating hs-cTnTamong COPD
patients in the stable state. The objectives of the
study were therefore to (A) compare the distribution
of hs-cTnTamong patients with stable COPD with a
random sample from the general population and (B)
assess the association between pulmonary function
and hs-cTnTamong patients with stable COPD.
MATERIALS AND METHODS
Study population
This is a prospectively designed, cross-sectional
case-control study that includes a consecutive
sample of 101 stable COPD patients from the
Akershus University Hospital’s outpatient clinic,
and a random sample of 120 references from the
general population from the Akershus University
Hospital’s catchment area. Patients with a history
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of congestive heart failure (CHF), MI, angina pectoris, percu-
taneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) were not included. References with a diagnosis
of COPD, or history of CHF, MI, PCI or CABG were excluded
(n=9). The study protocol was approved by the committee for
medical and health research ethics, Southeastern Norway, and
all patients provided written informed consent.
Measurements
All subjects completed a questionnaire on smoking habits and
respiratory symptoms according to the MMRC (Modiﬁed
Medical Research Council) Dyspnea Scale. Spirometry with
reversibility testing with salbutamol was performed at the out-
patient clinic, as recommended by Miller.13 COPD patients
were classiﬁed into four categories (A–D) in accordance with
the combined COPD assessment of the revised GOLD strategy
document, including associations between symptoms (MMRC
Scale), spirometric classiﬁcations and future risk of exacerba-
tions.14 Smoking habits were expressed as current smoking (yes/
no) and cumulative tobacco exposure expressed as pack-years.
Arterial and venous blood was sampled after an overnight
fasting and tobacco-abstinent period; hs-cTnT was measured
with the Elecsys 2010 troponin T hs STAT assay, and
N-terminal-pro Brain Natriuretic Peptide (NT-proBNP) and
Interleukin-6 (IL6) were measured with the Cobas e602 (Roche
Diagnostics, Mannheim, Germany).
Statistical analyses
The statistical analyses were performed in three steps. First, all
variables were compared between the cases and the references
using a Student t test for continuous covariates and χ² test for
categorical covariates. Second, we investigated the univariate
associations between hs-cTnT and relevant covariates using a
Student t test for dichotomous covariates. We used a least
square univariate linear regression for continuous covariates
categorised in quartiles with log-transformed hs-cTnT (ln
(hs-cTnT)) as the dependent variable to detect linear trends.
Pearson correlation analyses were also performed in order to
investigate the association between relevant continuous determi-
nants for hs-cTnT. Measurements below the limit of blank
(LoB) and between the LoB and the limit of detection (LoD)15
were replaced with LoB/2 and LoD/2, respectively. For each cat-
egory of the covariate, hs-cTnTwas expressed as the geometric
mean. Third, we investigated the association between hs-cTnT
and COPD using multiple ordinary least square regression
adjusting for covariates that were associated with COPD, as well
as hs-cTnTwith corresponding p values less than 0.2. The initial
full model was reduced by backward elimination if the p value
for association between ln(hs-cTnT) and the covariate was
≥0.05, and if removal of the covariate did not change the asso-
ciation between ln(hs-cTnT) and COPD>20%. The results are
given as the antilog of the coefﬁcient of the corresponding cov-
ariate, which can be interpreted as the ratio between hs-cTnT
and one unit increase of the corresponding covariate. In the
analysis restricted to COPD patients, we used the same model
using COPD patient categories A–D as the explanatory variable
of interest. The analyses were performed using PASW Statistics
18 (SPSS, Inc, Chicago, Illinois, USA). For details please see
online supplementary data.
RESULTS
Comparison of the cases and the references
The crude geometric means of circulating hs-cTnT in the cases
and the references were 7.75 and 3.01 ng/l, respectively
(p<0.001); that is, a ratio of 2.57 (95% CI 2.05 to 3.23). The
distribution of hs-cTnT related to the LoB and the 99th percent-
ile in a healthy reference population is shown in ﬁgure 1. The
crude analyses indicated a dose-response relationship between
hs-cTnT and patient category (ﬁgure 2). The cumulative tobacco
exposure (expressed as pack-years) was signiﬁcantly higher
among the patients than the references (table 1), whereas the
prevalence of current smoking did not differ signiﬁcantly
between the cases and the references (p=0.127). Age, heart
rate, NT-proBNP, IL6, neutrophils, history of arterial hyperten-
sion, indices of left ventricular hypertrophy (LVH) (Sokolow–
Lyon criteria), and presence of pathological Q waves were sig-
niﬁcantly higher among the cases, although the absolute number
of patients with LVH (n=6) or pathological Q waves (n=4) was
low. None of the subjects had atrial ﬁbrillation. The cases and
the references did not markedly differ regarding gender, systolic
blood pressure, diabetes, use of a statin, serum creatinine or
presence of Twave inversion (p >0.2). The distributions of rele-
vant covariates between the cases and the references are shown
in table 1.
Univariate analysis of hs-cTnT
The univariate associations between hs-cTnT and covariates
among cases and control subjects are shown in table 2 (dichot-
omous covariates) and table 3 (continuous covariates by quar-
tiles). The majority of the dichotomous variables were
Figure 1 hs-cTnT, High-sensitivity cardiac troponin T; COPD, Chronic
obstructive pulmonary disease; 3 ng/l, limit of blank and 14 ng/l, 99th
percentile of healthy reference population.
Figure 2 hs-cTnT, High-sensitivity cardiac troponin T; chronic
obstructive pulmonary disease classiﬁcation after the Global Initiative
of Obstructive Lung Disease strategy document, revised 2011.
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associated with hs-cTnT, except current smoking. Among the
continuous variables, body mass index, heart rate, blood haemo-
globin and serum creatinine were not signiﬁcantly associated
with hs-cTnT (table 3). Creatinine was, however, included in
the initial multivariate regression model, as creatinine is an
established factor associated with circulating troponin levels.
Multivariate analysis
In the ﬁnal multivariate model, we found that the ratio of
hs-cTnT between cases and references was 1.65 (1.31–2.08,
p<0.001). We also found a signiﬁcant relation between hs-cTnT
and forced expiratory volume in one second (FEV 1) (ratio
(95% CI): 0.74 (0.65 to 0.83), p=0.001 in the total cohort,
and that hs-cTnT was signiﬁcantly higher among subjects with
pathological Q waves and ECG signs of LVH as compared with
their counterparts. Moreover, hs-cTnTwas signiﬁcantly lower in
females than in males, and increased signiﬁcantly with higher
age. The coefﬁcient for the product of age and population
group (case/reference) was not signiﬁcant. Subjects with IL6
levels above the detection limit (LoD=1.5 pg/ml) had signiﬁ-
cantly higher hs-cTnT than subjects with IL6 below the detec-
tion limit. We found, however, no signiﬁcant independent
association between hs-cTnT and cumulative tobacco use
Table 1 Characteristics of the total cohort, stable chronic obstructive pulmonary disease patients and references
Covariate Total Cases References p Value
Total, n 212 101 111 <0.001
hs-cTnT, ≥3 ng/l, n (%) 145 (68.4) 87 (86.1) 58 (52.3) <0.001
hs-cTnT, geometric mean 4.72 7.75 3.01 <0.001
Demographic data
Age, years mean (SD) 59 (10.0) 64 (7.5) 54 (9.7) <0.001
Female, n (%) 104 (49.1) 51 (50.5) 53 (47.7) 0.689
BMI, kg/m2 mean (SD) 25.6 (4.6) 25.1 (4.9) 26.1 (4.4) 0.102
Smoking habit
Pack-years, mean (SD) 21.3 (20.8) 36.6 (17.6) 7.3 (11.6) <0.001
Current smoker, n (%) 47 (22.2) 27 (26.7) 20 (18.0) 0.127
Spirometry
FVC, litre mean (SD) 3.5 (1.4) 2.7 (1) 4.3 (1.3) <0.001
FEV1, litre mean (SD) 2.3 (1.3) 1.3 (0.6) 3.2 (1) <0.001
FEV1/FVC, % mean (SD) 62.6 (17.5) 47.4 (12.8) 76.3 (6.4) <0.001
FEV1/height2, litre/m2 mean (SD) 0.8 (0.4) 0.4 (0.2) 1.1 (0.2) <0.001
Clinical data
Syst BP, mm Hg mean (SD) 136.4 (20) 137.8 (21.4) 135.3 (18.7) 0.360
Arterial HT, n (%) 48 (22.6) 35 (34.7) 13 (11.7) <0.001
Diabetes mellitus, n (%) 8 (3.8) 3 (3.0) 5 (4.5) 0.558
Statin, n (%) 20 (9.4) 10 (9.9) 10 (9) 0.824
Laboratory data
Haemoglobin, g/dl mean (SD) 14.3 (1.2) 13.8 (1.1) 14.8 (1.1) <0.001
NT-pro BNP, pmol/l, median (IQR) 7.8 (12.7) 13.4 (15.1) 5.5 (7.7) <0.001
IL6, pg/ml, median (IQR) 0.8 (2.1) 2.1 (3.2) 0.8 (0.9) 0.016
Neutrophils, 109/l mean (SD) 3.8 (1.4) 4.3 (1.5) 3.3(1.2) <0.001
Creatinine, mg/dl mean (SD) 0.8 (0.2) 0.8 (0.2) 0.8 (0.1) 0.331
ECG
Heart rate, n/min mean (SD) 67 (12.0) 70 (12.4) 65 (10.5) 0.005
Pathological Q wave, n (%) 4 (1.9) 4 (4) 0 (0) 0.034
T wave inversion, n (%) 7 (3.3) 3 (3.0) 4 (3.6) 0.797
Left ventricular hypertrophy, n (%) 7 (3.3) 6 (5.9) 1 (0.9) 0.040
Right ventricular hypertrophy, n (%) 3 (1.4) 3 (3.0) 0 (0) 0.067
P pulmonale, n (%) 7 (3.3) 7 (6.9) 0 (0) 0.005
BMI, body mass index; FEV, forced expiratory volume; FVC, forced vital capacity; HT, hypertension; hs-cTnT, high-sensitivity cardiac troponin T; IL, interleukin; NT-pro BNP, N-terminal
probrain natriuretric pepride; one pack-year, 20 cigarettes daily during 1 year, Syst BP: systolic blood pressure.
Table 2 Geometric mean of high-sensitive cardiac troponin T
(hs-cTnT in ng/l) by dichotomous covariates, and the ratio of
geometric mean of hs-cTnT
Covariate
Covariate
present Ratio p Value
Yes No
Demographic data
Female 3.80 5.81 0.65 <0.001
Smoking habit
Current smoker 4.24 4.87 0.87 0.289
Clinical data
COPD 7.75 3.01 2.57 <0.001
Hypertension 7.18 4.18 1.72 <0.001
Laboratory data
IL6 (≥1.5 pg/ml) 7.50 3.29 2.28 <0.001
Electrocardiogram
Pathological Q wave 19.38 4.60 4.21 0.013
Left ventricular hypertrophy 15.60 4.53 3.44 0.003
Right ventricular hypertrophy 28.90 4.60 6.28 0.005
COPD, chronic obstructive pulmonary disease; IL6, interleukin 6.
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(p=0.123), current smoking (p=0.195), history of hypertension
(p=0.594), serum NT-proBNP concentration (p=0.111), heart
rate (p=0.684), blood neutrophil count (p=0.682) or serum
creatinine concentration (p=0.926), when added to the ﬁnal
model. The ratio of hs-cTnT was attentuated to 1.61 (1.28–
2.04) when p pulmonale was added to the ﬁnal model, but p
pulmonale was not independently associated with hs-cTnT in
the total study cohort.
hs-cTnT among COPD patients
In the analysis restricted to the COPD patients, we found a sig-
niﬁcant positive association between hs-cTnT and the severity of
disease. In COPD patients, the crude analyses indicated a
dose-response relationship between hs-cTnTand patient categor-
ies A–D (ﬁgure 2). This positive association remained signiﬁcant
after multivariate adjustment (p trend <0.001). A similar rela-
tion was observed between hs-cTnT and FEV1 (ratio: 0.61
(0.48–0.79), p=0.001). The signiﬁcant positive association
between FEV1 and hs-cTnT among the patients only was not
changed after inclusion of p pulmonale in the model. The asso-
ciations between hs-cTnTand age, gender, pack-years and indices
of left and right ventricular hypertrophy were not signiﬁcant
among stable COPD patients. Arterial blood oxygen and carbon
dioxide tension, diffusing capacity for carbon monoxide and
presence of p pulmonale were not signiﬁcantly associated with
hs-cTnT in our patient group. The association between hs-cTnT
and IL6 levels (p <0.001) and the presence of pathological Q
waves (p=0.023) were highly signiﬁcant among stable COPD
patients. Among the reference subjects, there was no signiﬁcant
association between hs-cTnT and pulmonary function (FEV1),
and a weak signiﬁcant association with IL6 above LoD
(p=0.040). We found, however, signiﬁcant associations between
hs-cTnTand age or gender among the references (table 4).
DISCUSSION
Principal ﬁndings
The new and salient ﬁnding of this study is that COPD patients
in their stable state without a history of coronary heart disease
have higher circulating levels of troponin T than a reference
population drawn randomly from the general population. This
association remained highly signiﬁcant after multivariate adjust-
ment. Among the cases, we found a dose-response relationship
Table 4 The relative change in high-sensitive cardiac troponin T (hs-cTnT) (95% CI) by relevant covariates
Covariate (C) Change of C (Δx)
Hs-cTnTx+Δx/hs-cTnTx
Total cohort COPD cases References
COPD Yes versus no 1.65 (1.31–2.08) – –
FEV1 Quartiles – 0.61 (0.48–0.79) 1.08 (0.83–1.41)
Age Quartiles 1.23 (1.12–1.36) 1.07 (0.89–1.27) 1.36 (1.19–1.55)
Female Yes versus no 0.63 (0.52–0.77) 0.71 (0.51–1.00) 0.52 (0.38–0.70)
IL6≥LoD Yes versus no 1.48 (1.19–1.84) 1.79 (1.28–2.51) 1.32 (1.01–1.72)
Q wave Yes versus no 2.35 (1.11–4.94) 2.56 (1.14–5.71) NA
LVH Yes versus no 2.01 (1.13–3.54) 1.97 (1.00–3.80) NA
RVH Yes versus no 3.06 (1.30–7.16) 2.31 (0.92–5.85) NA
COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume in 1 s; LoD, limit of detection; LVH, left ventricular hypertrophy; NA, not available (0–1 patient only); RVH,
right ventricular hypertrophy.
Table 3 Geometric mean of high-sensitivity cardiac troponin T (hs-cTnT) by quartiles of continuous covariates
Covariate Quartile (Qn) of covariate Ratio p Value
Q1 Q2 Q3 Q4
Demographic data
Age, (52; 60; 66) years 2.64 4.23 5.78 8.58 1.47 <0.001
BMI, (22; 25.2; 28.7) kg/m2 5.45 4.31 4.57 4.64 0.96 0.483
Pack-years (0; 19.3; 35.1) 2.86 4.35 6.26 6.95 1.36 <0.001
Clinical data
Heart rate, (57; 66; 75) 1/min 4.68 4.19 4.01 6.23 1.09 0.155
Systolic BP, (125; 135; 150) mm Hg 3.31 4.87 6.01 5.78 1.23 0.001
Spirometry
FVC, (2.50; 3.32; 4.36) litre 8.14 4.97 3.23 3.79 0.76 <0.001
FEV1, (1.28; 2.30; 3.10) litre 11.34 4.60 2.69 3.50 0.67 <0.001
FEV1/FVC, (47; 68; 77) % 11.34 4.38 3.32 2.99 0.65 <0.001
Laboratory data
NT-proBNP, (3.7; 7.8; 16.4) pmol/l 3.56 3.51 5.08 7.80 1.31 <0.001
Neutrophils, (2.8; 3.5; 4.5) 109/l 3.53 4.04 4.64 7.64 1.28 <0.001
Haemoglobin, (13.5; 14.3; 15.1) g/dl 6.56 4.15 4.49 4.36 0.90 0.087
Creatinine, (0.72; 0.80; 0.93) mg/dl 4.71 3.90 5.14 5.24 1.06 0.352
Ratio: (hs-cTnT)Qn/(hs-cTnT)Qn−1. Quartile limits in parentheses.
BMI; body mass index; BP, blood pressure; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s.
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between hs-cTnT and the severity of disease. To our knowledge,
this is the ﬁrst study to show that high-sensitivity cardiac tropo-
nin T levels in peripheral blood are increased in stable COPD
patients compared with their healthy references.
Pathophysiology of COPD and chronic, low-grade myocardial
injury
COPD appears to be an important independent determinant of
circulating troponin, expressed as hs-cTnT. Several underlying
mechanisms for the association between COPD and troponin T
should be considered. First, the prevalence of cardiovascular
disease is higher in COPD patients than in the general popula-
tion.16 17 Existing explanatory models for a relation between
COPD and cardiovascular disease (CVD) include inﬂammation,
hyperinﬂation and shared risk factors and genetics.18 The
inﬂammatory process in COPD involves neutrophils, macro-
phages and T lymphocytes, and augmented concentrations of
inﬂammatory markers, such as IL6 have been reported.19 20
Spillover of inﬂammatory mediators from the lungs to the
systemic circulation has been proposed as a possible link
between COPD and comorbidities.2
Concerning measurement of hs-cTnT, large-scale population-
based epidemiological studies have shown that multiple factors
are associated with chronic, low-grade troponin elevation;10 11
thus, increasing age, male gender, hypertension, diabetes melli-
tus and reduced renal function have all been shown to be asso-
ciated with higher hs-cTnT levels in the general population.10 21
Moreover, signiﬁcant associations between cTnTand biomarkers
of inﬂammation have been observed.11 In the current study,
patients with a history of CAD were not included. Due to
common risk factors between COPD and CAD, subclinical ath-
erosclerosis still may be common in patients with COPD.18
Accordingly, it is not surprising that almost 4% of the patients
had pathological Q waves in their ECG, and that Q wave, as
well as LVH, was signiﬁcantly associated with hs-cTnT even
after adjustment for relevant covariates. However, NT-proBNP
concentrations were not signiﬁcantly associated with hs-cTnT in
the current study population. B-type natriuretic peptides are
markers of haemodynamic stress22 and powerful markers of
outcome across the spectrum of cardiovascular disease.23 In the
current study, NT-proBNP concentrations were signiﬁcantly
higher in cases than in references, but there were no individuals
with measurements above the normal range, suggesting that our
COPD patients did not have unrecognised heart failure. Cases
had a higher prevalence of hypertension, but the mean systolic
blood pressure was within normal range, suggesting that the
hypertension was fairly well controlled.
Hypoxaemia has been suggested as an explanatory factor for
myocardial damage and leakage of troponin in the setting of
pulmonary embolism.24 We did not, however, ﬁnd any associ-
ation between hs-cTnT and arterial oxygen or carbon dioxide
tension among the COPD patients (data not shown). This could
be due to the fact that the mean oxygen tension was higher than
8.0 kPa, and that the lowest value was 7.2 kPa. Admittedly, the
lack of association between hypoxaemia and hs-cTnT could also
be explained by insufﬁcient study power. However, in a retro-
spective and prospective study of troponin in COPD exacerba-
tion, we also failed to ﬁnd any association between hypoxaemia
and troponin levels.25 26
Another mechanism contributing to troponin elevation in
COPD may be increased inﬂammatory activity. Elevated tropo-
nin levels are frequently found in acute disease with a major
inﬂammatory component, such as sepsis.27 Previous studies
suggest that IL6 might play a salient role in the inﬂammatory
responses in COPD28 as well as in cardiovascular disease.29 Our
results indicate that IL6 above the detection limit is a signiﬁcant
determinant of hs-cTnT levels. This observation suggests that
troponin release in COPD may, at least partially, be mediated by
an inﬂammatory process that involves IL6. Theoretically, proin-
ﬂammatory cytokines, like tumour necrosis factor (TNF-α),
IL1β and IL6 derived from activated neutrophils could increase
the permeability of the cell wall of cardiomyocytes and promote
troponin release or apoptosis of cardiomyocytes.30 In our
model, neutrophils were not signiﬁcantly associated with
hs-cTnT, even after exclusion of IL6 from the model. This could
be due to additional activity and IL6-secretion from, for
instance T cells and macrophages.
Potential clinical implications
The fact that low-grade myocardial damage among COPD
patients seems to be present even in the stable state of the
disease strengthens the need to understand the pathogenic, espe-
cially immunologic, mechanisms in COPD and its comorbidities
in order to be able to develop new strategies for the prevention
and treatment of this condition. Although associated with
increased risk, there is at present no consensus for the use of
hs-cTnT as a screening tool, and there are no established cut-off
points for hs-cTnT to guide therapy in settings other than acute
coronary syndromes. Since chronic, low-grade increase of circu-
lating troponin can be due to both ischaemic and non-ischaemic
causes, it is important to be able to distinguish between these
aetiologies. Stable COPD patients without previously known
coronary heart disease or CHF presenting with elevated levels
of hs-cTnT may, therefore, be candidates for cardiac investiga-
tions, such as echocardiography and stress testing. Such a strat-
egy may prove effective in identifying a subgroup of stable
COPD patients who potentially could beneﬁt from cardiovascu-
lar interventions and therapies, such as antiplatelet therapy,
treatment with statins or referral for coronary angiography.
However, further validation of the current results, deﬁnition of
appropriate cut-off values for troponins for referral to cardiac
investigations, and clinical trials to demonstrate efﬁcacy and
cost-effectiveness are clearly required before such a strategy can
be recommended in clinical practice.
Strengths and limitations
Major strengths of the study include the participation of stable
COPD patients, including patients in all GOLD stages. Several
prior studies have included COPD patients hospitalised with an
acute exacerbation, but those results may not be extrapolated to
the stable state. First, an acute exacerbation is commonly asso-
ciated with respiratory infection and inﬂammation that could
inﬂuence the rate of troponin release. Second, there is increasing
evidence that patients with frequent COPD exacerbations may
represent a separate phenotype distinct from stable patients.
Other strengths of our study include the relatively similar sizes
of patients and references as well as balanced representation of
men and women. Smokers are well represented among the refer-
ences. The main limitation of the study is the cross-sectional
design that precludes any causative interpretation of the results.
The fact that the COPD group had a prevalence of 4% patho-
logical Q waves, suggesting unrecognised cardiac injury in a
small minority of patients, is another limitation. However, a sen-
sitivity analysis excluding these subjects did not reveal a signiﬁ-
cant change in the association between hs-cTnT and the relevant
covariates.
The selection of COPD patients from the outpatient clinic
may have resulted in a group of patients with more severe
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symptoms, including comorbidities, than non-selected COPD
patients from a general population. The latter issue is, however,
of minor concern as we have registered the majority of variables
that constitute broad aspects of the health problems in COPD
patients. The representativeness of the references may also be
questioned. Thus, we compared the distribution of age and
gender in the source population in the same period, that is,
from 2006 to 2010. It turned out that 50% of the population in
this age group in Akershus County were female, and the distri-
bution of subjects of the age groups 40–49, 50–64 and 65 years
or older was 39%, 45% and 17%, respectively (accessed from
the Norwegian Central Statistics Ofﬁce, table 07459, July
2011). Hence, our sample is likely to be representative for the
source population.
CONCLUSION
Stable COPD is associated with elevated cardiac troponin T
levels, and the hs-cTnT levels increase with the severity of
airﬂow limitation. Higher hs-cTnT levels are associated with
higher IL6 concentrations and pathological Q waves, suggesting
that inﬂammatory activity, as well as unrecognised MI, may con-
tribute to higher hs-cTnT concentrations in stable COPD.
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increased in stable COPD
High-sensitivity cardiac troponin T levels are
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